MedTrace Logo

CMPA-GO Study: Growth and Safety Outcomes in Infants With CMPA Fed a Novel Extensively Hydrolyzed Formula

NCT06830681 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2025-06-29

No results posted yet for this study

Summary

CMPA-GO Study: Growth and safety Outcomes in infants with CMPA fed a novel extensively hydrolyzed formula

Conditions

  • Cow Milk Protein Allergy

Interventions

DIETARY_SUPPLEMENT

New generation eHF

New generation of a whey-based eHF formula intended for the dietary management of infants with CMPA.

DIETARY_SUPPLEMENT

Commercial eHF

Commercial whey-based eHF formula intended for the dietary management of infants with CMPA.

Sponsors & Collaborators

  • Société des Produits Nestlé (SPN)

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
4 Weeks
Max Age
22 Weeks
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-07
Primary Completion
2025-05-23
Completion
2025-06-23

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06830681 on ClinicalTrials.gov